Return to Investors
Posted on Sunday, May 24th, 2020Ventilators are not designed to sit in storage for long periods of time unused. But that’s precisely what’s often required of this medical device, which then may require substantial repair and updates before it is functional. That’s a tale that’s been told repeatedly in this pandemic. [...]
Posted on Wednesday, May 22nd, 2019May 25, 2019 – Reprieve Cardiovascular™, a pioneering medical device company focused on improving outcomes for patients suffering from Acute Decompensated Heart Failure (ADHF), announced the results of two non-randomized, prospective clinical trials in patients hospitalized with Acute Heart Failure (AHF). The two studies demonstrate that using Reprieve-Guided Diuretic Therapy, the first fully automated fluid [...]
Posted on Wednesday, April 3rd, 2019Jim Dillon, President & CEO, Reprieve Cardiovascular, and Dr. Howard Levin, President, and Chief Medical Officer, Coridea, presented Reprieve’s innovative approach for heart failure therapy at the Med Tech Strategist Innovation Summit, April 9-11, in Dublin. The conference is recognized as the leading medical technology investment forum in Europe and brings together more than 450 [...]Show All
Unexpected device solutions that change the lives of cardiac, pulmonary, renal, and neuro patients worldwide.
With leading physicians and investors, create physiologically-based solutions for specific clinical problems that are too complex or costly for others to solve.
Using seed funding and funding from SBIR government grants, work with global academic institutions to test solutions. Expand these ideas into high-impact solutions that create new Series A funded companies fueled for development.
10 companies launched. $1.2 billion return on investment. Our goals: Expand our portfolio. Launch one new company every year. Bridge the gap between business and medical device innovation.